{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:06:33Z","timestamp":1790258793127,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BeOne Medicines Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/03saz3d95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with metastatic non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (ES-SCLC) have poor prognosis and survival with current standard of care. Several checkpoint inhibitor combinations have been evaluated clinically. We report outcomes from the dose-expansion cohorts of patients with NSCLC or ES-SCLC from the AdvanTIG-105 clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      AdvanTIG-105 was a phase I\/Ib, open-label, multicenter clinical trial of ociperlimab plus tislelizumab with or without chemotherapy in patients with unresectable locally advanced or metastatic solid tumors, including NSCLC and ES-SCLC (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04047862\">NCT04047862<\/jats:ext-link>\n                      ). The dose-expansion cohorts received ociperlimab (anti-T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domain) 900\u2009mg intravenously and tislelizumab (anti-programmed cell death-protein 1) 200\u2009mg intravenously every 3 weeks (Q3W) \u00b1 chemotherapy for four cycles, followed by ociperlimab 900\u2009mg intravenously and tislelizumab 200\u2009mg intravenously Q3W. The primary endpoint was the objective response rate. Other key endpoints included duration of response and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of August 7, 2024, patients with untreated squamous NSCLC (sqNSCLC; n=41), untreated non-sqNSCLC (n=43), untreated programmed cell death-ligand 1+ NSCLC (tumor cell \u22651%; n=45), checkpoint inhibitor-experienced NSCLC (n=26), and untreated ES-SCLC (n=43) were treated in the dose-expansion phase; of these, 40, 42, 45, 26, and 41 patients, respectively, were efficacy evaluable. ORR (95%\u2009CI) was 55.0% (38.5% to 70.7%), 54.8% (38.7% to 70.2%), 40.0% (25.7% to 55.7%), 7.7% (0.9% to 25.1%), and 65.9% (49.4% to 79.9%), respectively. Median (95%\u2009CI) DOR was 16.9 (5.6 to not estimable (NE)), 13.9 (8.2 to NE), 14.0 (2.9 to NE), 15.9 (12.6 to NE), and 4.1 (3.4 to 5.6) months, respectively. Median (95%\u2009CI) progression-free survival was 8.2 (6.0 to 18.1), 11.3 (8.0 to 20.7), 5.5 (4.2 to 8.2), 2.9 (1.4 to 5.3), and 4.9 (4.2 to 5.5) months, respectively. Treatment-related treatment-emergent adverse events (TR-TEAEs) were experienced by 39 (95.1%), 41 (95.3%), 38 (84.4%), 19 (73.1), and 39 (90.7%) patients, respectively, with 24 (58.5%), 26 (60.5%), 9 (20.0%), 6 (23.1%), and 23 (53.5%) experiencing Grade 3\u20134 TR-TEAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ociperlimab and tislelizumab\u00b1chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in patients with NSCLC or ES-SCLC. Findings from this small phase I study should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015474","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:45:10Z","timestamp":1790257510000},"page":"e015474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["AdvanTIG-105: a phase I\/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04047862","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04047862","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"first","affiliation":[{"name":"Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[{"name":"Affiliated Tumor Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"OSF HealthCare Cancer Institute and University of Illinois College of Medicine, Peoria, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[{"name":"Gachon University Gil Medical Center, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research, Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-906X","authenticated-orcid":false,"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0180-189X","authenticated-orcid":false,"given":"Youngjoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Lung Cancer, National Cancer Center, Goyang, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"Clay","sequence":"additional","affiliation":[{"name":"St John of God Subiaco Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan"},{"name":"School of Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyuan","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Zuo","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Sun","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9070","authenticated-orcid":false,"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026092406450707000_14.9.e015474.1","unstructured":"World Health Organization . World Health Organization (WHO) cancer fact sheet, 2025. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer [Accessed 4 Nov 2025]."},{"key":"2026092406450707000_14.9.e015474.2","unstructured":"American Cancer Society . Cancer facts & figures 2023, 2023. Available: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf [Accessed 4 Nov 2025]."},{"key":"2026092406450707000_14.9.e015474.3","unstructured":"PDQ Adult Treatment Editorial Board . PDQ cancer information summaries. Bethesda (MD): National Cancer Institute (US), 2025."},{"key":"2026092406450707000_14.9.e015474.4","doi-asserted-by":"crossref","first-page":"113581","DOI":"10.1016\/j.ejca.2024.113581","article-title":"Recent advances and future strategies in first-line treatment of ES-SCLC","volume":"200","author":"Gomez-Randulfe","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026092406450707000_14.9.e015474.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01881"},{"key":"2026092406450707000_14.9.e015474.6","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2024.1611713","article-title":"The role of immunotherapy in early-stage and metastatic NSCLC","volume":"30","author":"Lieber","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"2026092406450707000_14.9.e015474.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2026092406450707000_14.9.e015474.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2026092406450707000_14.9.e015474.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"2026092406450707000_14.9.e015474.10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","volume":"19","author":"Cheng","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"key":"2026092406450707000_14.9.e015474.11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363"},{"key":"2026092406450707000_14.9.e015474.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"2026092406450707000_14.9.e015474.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"2026092406450707000_14.9.e015474.14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"2026092406450707000_14.9.e015474.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"2026092406450707000_14.9.e015474.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2026092406450707000_14.9.e015474.17","doi-asserted-by":"crossref","DOI":"10.1200\/OA.0000000000000001","article-title":"Small Cell Lung Cancer: New Hope, New Challenges","volume":"1","author":"Desai","year":"2024","journal-title":"JCO Oncology Advances"},{"key":"2026092406450707000_14.9.e015474.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"2026092406450707000_14.9.e015474.19","doi-asserted-by":"crossref","first-page":"828319","DOI":"10.3389\/fimmu.2022.828319","article-title":"An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2026092406450707000_14.9.e015474.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02821","article-title":"Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Immunol"},{"key":"2026092406450707000_14.9.e015474.21","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"2026092406450707000_14.9.e015474.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026092406450707000_14.9.e015474.23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026092406450707000_14.9.e015474.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026092406450707000_14.9.e015474.25","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad009","article-title":"TIGIT-based immunotherapeutics in lung cancer","volume":"3","author":"Patel","year":"2023","journal-title":"Immunother Adv"},{"key":"2026092406450707000_14.9.e015474.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"2026092406450707000_14.9.e015474.27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT051","article-title":"Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC","volume":"85","author":"Peters","year":"2025","journal-title":"Cancer Res"},{"key":"2026092406450707000_14.9.e015474.28","doi-asserted-by":"crossref","first-page":"101025","DOI":"10.1016\/j.iotech.2024.101025","article-title":"LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC)","volume":"24","author":"Socinski","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"key":"2026092406450707000_14.9.e015474.29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005829","article-title":"AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors","volume":"11","author":"Frentzas","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092406450707000_14.9.e015474.30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","article-title":"Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2026092406450707000_14.9.e015474.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2026092406450707000_14.9.e015474.32","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2021.04.014"},{"key":"2026092406450707000_14.9.e015474.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.010"},{"key":"2026092406450707000_14.9.e015474.34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0913"},{"key":"2026092406450707000_14.9.e015474.35","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT053","article-title":"Abstract CT053: Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res"},{"key":"2026092406450707000_14.9.e015474.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"2026092406450707000_14.9.e015474.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.027","article-title":"OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study","volume":"18","author":"Cheng","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"2026092406450707000_14.9.e015474.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"2026092406450707000_14.9.e015474.39","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz063","article-title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1\u2013positive locally advanced\/metastatic NSCLC","volume":"30","author":"Mok","year":"2019","journal-title":"Annals of Oncology"},{"key":"2026092406450707000_14.9.e015474.40","doi-asserted-by":"crossref","first-page":"101443","DOI":"10.1016\/j.iotech.2025.101443","article-title":"244MO AdvanTIG-302: Phase III study of ociperlimab (OCI) + tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death-ligand 1 (PD-L1) high, untreated, locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)","volume":"28","author":"Reck","year":"2025","journal-title":"Immuno-Oncology and Technology"},{"key":"2026092406450707000_14.9.e015474.41","unstructured":"BeOne Medicines . BeiGene provides update on the ociperlimab (BGB-A1217) Clinical Development Program, 2025. Available: https:\/\/ir.beonemedicines.com\/news\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/4f7a71c1-cb84-4fa6-b562-65c239f04bc6 [Accessed 4 Nov 2025]."},{"key":"2026092406450707000_14.9.e015474.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002"},{"key":"2026092406450707000_14.9.e015474.43","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a\/1b Nonrandomized Controlled Trial","volume":"9","author":"Kim","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026092406450707000_14.9.e015474.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:45:16Z","timestamp":1790257516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,24]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015474"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015474","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}